INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2010

Saffron supplementation improved cognitive function in patients with mild to moderate Alzheimer's disease.

In a 16-week randomized, double-blind, placebo-controlled trial, 46 patients with mild to moderate Alzheimer's disease received 30 mg daily of saffron or a placebo. Saffron produced significantly better cognitive outcomes than placebo on the ADAS-cog scale (P = 0.04) and clinical dementia rating (P = 0.04). No significant differences between groups were observed for adverse events.

Study type
Randomized controlled trial
Who was studied
46 patients with mild to moderate Alzheimer's disease
What was measured
Cognitive function and dementia rating scores

THE PAPER

Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial.

Akhondzadeh S, Sabet MS, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SSh, Yousefi MH, Alimardani R, Jamshidi A, Zare F, Moradi A. J Clin Pharm Ther, 2010.

PubMed 20831681 ↗DOI 10.1111/j.1365-2710.2009.01133.x ↗

Brain & moodHealthy aging & longevity

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.